Integral Health Asset Management LLC Purchases Shares of 550,000 Envista Holdings Corporation $NVST

Integral Health Asset Management LLC purchased a new position in Envista Holdings Corporation (NYSE:NVST) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 550,000 shares of the company’s stock, valued at approximately $11,204,000.

Several other large investors have also added to or reduced their stakes in the company. Holocene Advisors LP acquired a new position in shares of Envista in the second quarter valued at about $43,936,000. Norges Bank purchased a new stake in shares of Envista in the 2nd quarter valued at $40,229,000. Alliancebernstein L.P. boosted its holdings in shares of Envista by 34.0% in the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after acquiring an additional 1,547,656 shares during the last quarter. Franklin Resources Inc. grew its position in Envista by 16.7% during the 2nd quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock worth $175,011,000 after purchasing an additional 1,284,767 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Envista by 22.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,905,149 shares of the company’s stock valued at $59,178,000 after buying an additional 523,949 shares during the last quarter.

Insider Activity

In other news, SVP Mischa Reis sold 9,675 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the sale, the senior vice president directly owned 32,382 shares in the company, valued at $971,460. This represents a 23.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.66% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on NVST shares. Zacks Research upgraded Envista from a “hold” rating to a “strong-buy” rating in a research note on Friday, February 6th. Evercore reiterated an “outperform” rating and issued a $32.00 target price on shares of Envista in a research note on Friday, February 6th. Stifel Nicolaus set a $31.00 price target on shares of Envista in a report on Friday, February 6th. Mizuho lifted their price target on Envista from $24.00 to $27.00 and gave the company a “neutral” rating in a research note on Tuesday, February 10th. Finally, Barclays increased their price target on Envista from $24.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $27.75.

Envista Price Performance

Shares of Envista stock opened at $24.62 on Friday. The stock has a market capitalization of $4.03 billion, a P/E ratio of 87.91, a PEG ratio of 1.74 and a beta of 0.95. The business has a 50 day simple moving average of $26.20 and a two-hundred day simple moving average of $22.58. Envista Holdings Corporation has a 12 month low of $14.22 and a 12 month high of $30.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.38 and a quick ratio of 2.04.

Envista (NYSE:NVST) last announced its earnings results on Thursday, February 5th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.06. Envista had a net margin of 1.73% and a return on equity of 6.54%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, analysts predict that Envista Holdings Corporation will post 1 EPS for the current fiscal year.

Envista Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.